Screener
aTyr Pharma ATYR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | $6,748 | $15,384 | 14,065 | 27,198 |
| General and administrative | 4,133 | 4,929 | 8,252 | 8,888 |
| Total operating expenses | 10,881 | 20,313 | 22,317 | 36,086 |
| Loss from operations | (10,881) | (20,313) | (22,317) | (36,086) |
| Total other income (expense), net | 571 | 781 | 1,215 | 1,673 |
| Consolidated net loss | (10,310) | (19,532) | (21,102) | (34,413) |
| Net loss attributable to noncontrolling interest in Pangu BioPharma Limited | 1 | 1 | 2 | 2 |
| Net loss attributable to aTyr Pharma, Inc. | $(10,309) | $(19,531) | $(21,100) | $(34,411) |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's operating income?
- aTyr Pharma (ATYR) reported operating income of -$10.88M in Q2 2026.
- How has aTyr Pharma's operating income changed year-over-year?
- aTyr Pharma's operating income increased by 46.4% year-over-year, from -$20.31M to -$10.88M.
- What is the long-term trend for aTyr Pharma's operating income?
- Over 4 years (2021 to 2025), aTyr Pharma's operating income has grown at a 22.9% compound annual growth rate (CAGR), from -$34.02M to -$77.63M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about aTyr Pharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude